Related Experiment Video
Updated: Jul 2, 2026

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
Shubham Pant1, Meena P Chilukuri, Bhuvaneswari Ramaswamy
1Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Columbus, Ohio, USA.
Abstract:
Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast cancer. Clinical trials using combinations of taxanes with targeted therapy have also shown considerable activity in breast cancer. This article reviews the pharmacology of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with node-positive breast cancer.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
